<!DOCTYPE html>
<html lang="tr">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diyabetik BÃ¶brek HastalÄ±ÄŸÄ±: Yeni Tedavi YÃ¶ntemleri ve Koruma Stratejileri | UzunYaÅŸa Blog</title>
    <meta name="description" content="Diyabetik bÃ¶brek hastalÄ±ÄŸÄ±nda kanÄ±ta dayalÄ± tedavi yaklaÅŸÄ±mlarÄ±: SGLT2 inhibitÃ¶rleri, GLP-1 agonistleri, finerenon ve yaÅŸam tarzÄ± mÃ¼dahaleleri. CREDENCE, DAPA-CKD, FLOW ve FIDELIO-DKD verilerine dayalÄ± gÃ¼ncel rehber.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/diyabetik-bobrek-hastaligi-yeni-tedavi-yontemleri-ve-koruma-.html">
    <meta property="og:title" content="Diyabetik BÃ¶brek HastalÄ±ÄŸÄ±: Yeni Tedavi YÃ¶ntemleri ve Koruma Stratejileri">
    <meta property="og:description" content="Diyabetik bÃ¶brek hastalÄ±ÄŸÄ±nda kanÄ±ta dayalÄ± tedavi yaklaÅŸÄ±mlarÄ±: SGLT2 inhibitÃ¶rleri, GLP-1 agonistleri, finerenon ve yaÅŸam tarzÄ± mÃ¼dahaleleri.">
    <meta property="og:image" content="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/diyabetik-bobrek-hastaligi-yeni-tedavi-yontemleri-ve-koruma-.html">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="og:locale" content="tr_TR">
    <meta property="article:published_time" content="2026-02-22">
    <meta property="article:section" content="Tedavi">
    <meta property="article:tag" content="diyabetik-bÃ¶brek-hastalÄ±ÄŸÄ±">
    <meta property="article:tag" content="SGLT2-inhibitÃ¶rleri">
    <meta property="article:tag" content="GLP1-agonistleri">
    <meta property="article:tag" content="bÃ¶brek-koruma">
    <meta property="article:tag" content="diyabet-tedavisi">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Diyabetik BÃ¶brek HastalÄ±ÄŸÄ±: Yeni Tedavi YÃ¶ntemleri ve Koruma Stratejileri">
    <meta name="twitter:description" content="Diyabetik bÃ¶brek hastalÄ±ÄŸÄ±nda kanÄ±ta dayalÄ± tedavi: SGLT2i, GLP-1 RA, finerenon ve yaÅŸam tarzÄ± mÃ¼dahaleleri.">
    <meta name="twitter:image" content="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Playfair+Display:wght@500;600&display=swap" rel="stylesheet">
    <link rel="icon" type="image/png" sizes="32x32" href="/favicon.png">
    <link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
    <script src="/scripts/https-redirect.js"></script>
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
    <script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments);}gtag('js',new Date());gtag('config','G-QBM7E0EHFP');</script>
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "Article",
      "headline": "Diyabetik BÃ¶brek HastalÄ±ÄŸÄ±: Yeni Tedavi YÃ¶ntemleri ve Koruma Stratejileri",
      "description": "Diyabetik bÃ¶brek hastalÄ±ÄŸÄ±nda kanÄ±ta dayalÄ± tedavi yaklaÅŸÄ±mlarÄ±: SGLT2 inhibitÃ¶rleri, GLP-1 agonistleri, finerenon ve yaÅŸam tarzÄ± mÃ¼dahaleleri.",
      "image": "https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop",
      "datePublished": "2026-02-22",
      "dateModified": "2026-02-22",
      "author": { "@type": "Organization", "name": "UzunYaÅŸa", "url": "https://uzunyasa.com" },
      "publisher": { "@type": "Organization", "name": "UzunYaÅŸa", "logo": { "@type": "ImageObject", "url": "https://uzunyasa.com/images/logo.svg" } },
      "mainEntityOfPage": "https://uzunyasa.com/pages/blog/diyabetik-bobrek-hastaligi-yeni-tedavi-yontemleri-ve-koruma-.html"
    }
    </script>
    <link rel="stylesheet" href="../../styles/main.css">
    <link rel="stylesheet" href="../../styles/animations.css">
    <style>
        article { max-width: 800px; margin: 0 auto; padding: 7rem 2rem 4rem; }
        .post-meta-top { display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 1.5rem; align-items: center; }
        .post-category { display: inline-block; background: #EC489920; color: #EC4899; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; }
        .reading-time { color: var(--text-gray); font-size: 0.9rem; }
        h1 { font-family: 'Playfair Display', serif; font-size: 2.5rem; font-weight: 600; line-height: 1.2; margin-bottom: 1rem; color: var(--text); }
        .subtitle { font-size: 1.15rem; color: var(--text-gray); margin-bottom: 2rem; line-height: 1.6; }
        .featured-image { width: 100%; height: 300px; border-radius: 16px; overflow: hidden; margin-bottom: 2rem; }
        .featured-image img { width: 100%; height: 100%; object-fit: cover; }
        .content p { margin-bottom: 1.5rem; font-size: 1.05rem; line-height: 1.8; }
        .content h2 { font-size: 1.6rem; font-weight: 700; margin: 3rem 0 1rem; color: var(--primary); padding-top: 1rem; border-top: 1px solid #e5e7eb; }
        .content h3 { font-size: 1.25rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text); }
        .content ul, .content ol { margin: 1.5rem 0; padding-left: 1.5rem; }
        .content li { margin-bottom: 0.5rem; font-size: 1.02rem; line-height: 1.7; }
        .content strong { color: var(--text); }
        .info-box { background: #eff6ff; border-left: 4px solid #3b82f6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
        .warning-box { background: #fef3c7; border-left: 4px solid #f59e0b; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
        .evidence-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
        .stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 1rem; margin: 2rem 0; }
        .stat-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.25rem; text-align: center; }
        .stat-card .number { font-size: 1.75rem; font-weight: 800; color: var(--primary); }
        .stat-card .label { font-size: 0.8rem; color: var(--text-gray); margin-top: 0.25rem; }
        table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; font-size: 0.95rem; }
        th, td { padding: 0.75rem; text-align: left; border-bottom: 1px solid #e5e7eb; }
        th { background: #f8fafc; font-weight: 600; color: var(--primary); }
        .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
        .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
        .author-box { display: flex; align-items: center; gap: 1rem; padding: 1.5rem; background: white; border-radius: 12px; border: 1px solid #e5e7eb; margin: 2rem 0; }
        .author-avatar { width: 60px; height: 60px; background: var(--primary); border-radius: 50%; display: flex; align-items: center; justify-content: center; color: white; font-weight: 700; }
        .author-info h4 { font-weight: 600; margin-bottom: 0.25rem; }
        .author-info p { font-size: 0.85rem; color: var(--text-gray); }
        @media (max-width: 640px) { h1 { font-size: 1.8rem; } article { padding: 6rem 1rem 3rem; } .stat-grid { grid-template-columns: repeat(2, 1fr); } }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-inner">
            <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
            <a href="../blog.html" class="back-link">â† Blog</a>
        </div>
    </header>

    <article>
        <div class="post-meta-top">
            <span class="post-category">ğŸ’Š Tedavi</span>
            <span class="reading-time">â± 14 dk okuma â€¢ 22 Åubat 2026</span>
        </div>

        <h1>Diyabetik BÃ¶brek HastalÄ±ÄŸÄ±: GÃ¼ncel Tedavi YaklaÅŸÄ±mlarÄ± ve Koruma Stratejileri</h1>
        <p class="subtitle">SGLT2 inhibitÃ¶rleri, GLP-1 reseptÃ¶r agonistleri ve nonsteroidal MRA'lar â€” diyabetik nefropatide farmakoterapinin hÄ±zla deÄŸiÅŸen yÃ¼zÃ¼. CREDENCE, DAPA-CKD, FLOW ve FIDELIO-DKD verilerine dayalÄ± gÃ¼ncel bir deÄŸerlendirme.</p>

        <div class="featured-image">
            <img src="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop" alt="Diyabetik BÃ¶brek HastalÄ±ÄŸÄ± tedavi yaklaÅŸÄ±mlarÄ±" loading="lazy">
        </div>

        <div class="content">

<p>Diyabetik bÃ¶brek hastalÄ±ÄŸÄ± (DKD), dÃ¼nyada son dÃ¶nem bÃ¶brek yetmezliÄŸinin en sÄ±k nedenidir ve diyabet prevalansÄ±nÄ±n artmasÄ±yla birlikte kÃ¼resel bir halk saÄŸlÄ±ÄŸÄ± sorunu haline gelmiÅŸtir. TÃ¼rkiye'de yaklaÅŸÄ±k 7 milyon diyabet hastasÄ± bulunmakta ve bu hastalarÄ±n %20-40'Ä±nda yaÅŸamlarÄ± boyunca bÃ¶brek tutulumu geliÅŸmektedir <sup>[1]</sup>.</p>

<p>Son on yÄ±lda DKD tedavisinde Ã¶nemli geliÅŸmeler yaÅŸandÄ±. Renin-anjiyotensin sistemi (RAS) blokajÄ±na ek olarak, SGLT2 inhibitÃ¶rleri, GLP-1 reseptÃ¶r agonistleri ve nonsteroidal mineralokortikoid reseptÃ¶r antagonistleri (ns-MRA) tedavi cephaneliÄŸine katÄ±ldÄ±. Bu yazÄ±da gÃ¼ncel verileri, kanÄ±t dÃ¼zeylerini ve klinik uygulamayÄ± deÄŸerlendiriyoruz.</p>

<h2>Diyabetik BÃ¶brek HastalÄ±ÄŸÄ±nÄ±n TanÄ±mÄ± ve Epidemiyolojisi</h2>

<p>DKD, kronik hipergliseminin glomerÃ¼ler, tÃ¼bÃ¼ler ve vaskÃ¼ler yapÄ±larda yol aÃ§tÄ±ÄŸÄ± ilerleyici bir hasardÄ±r. TanÄ± kriterleri:</p>

<ul>
<li><strong>AlbÃ¼minÃ¼ri:</strong> Ä°drar albÃ¼min/kreatinin oranÄ± (UACR) â‰¥30 mg/g (persistan)</li>
<li><strong>eGFR dÃ¼ÅŸÃ¼klÃ¼ÄŸÃ¼:</strong> &lt;60 mL/dk/1.73 mÂ² (en az 3 ay sÃ¼reyle)</li>
<li><strong>Veya her ikisi</strong> â€” diyabetik retinopati varlÄ±ÄŸÄ± tanÄ±yÄ± destekler</li>
</ul>

<div class="info-box">
<p><strong>ğŸ’¡ Klinik not:</strong> DKD tanÄ±sÄ± iÃ§in bÃ¶brek biyopsisi rutin olarak gerekmez. Ancak atipik seyir gÃ¶steren vakalarda (hÄ±zlÄ± eGFR dÃ¼ÅŸÃ¼ÅŸÃ¼, aktif idrar sedimenti, retinopati yokluÄŸunda aÄŸÄ±r proteinÃ¼ri) non-diyabetik bÃ¶brek hastalÄ±ÄŸÄ± ekarte edilmelidir <sup>[2]</sup>.</p>
</div>

<h2>Tedavinin Temelleri: YaÅŸam TarzÄ± MÃ¼dahaleleri</h2>

<p>Farmakoterapi Ã¶ncesinde ve eÅŸ zamanlÄ± olarak yaÅŸam tarzÄ± mÃ¼dahaleleri uygulanmalÄ±dÄ±r. Ancak ÅŸunu belirtmek gerekir: <strong>yaÅŸam tarzÄ± deÄŸiÅŸiklikleri tek baÅŸÄ±na ileri evre DKD'de yeterli deÄŸildir</strong> â€” kanÄ±tlanmÄ±ÅŸ farmakolojik tedavilerin yerine geÃ§emez, onlarÄ± tamamlar.</p>

<h3>Beslenme</h3>
<ul>
<li><strong>Protein alÄ±mÄ±:</strong> KDIGO 2024, eGFR &lt;30 olmayan DKD hastalarÄ±nda 0.8 g/kg/gÃ¼n protein alÄ±mÄ±nÄ± Ã¶nermektedir. Pratikte 70 kg bir birey iÃ§in bu gÃ¼nlÃ¼k ~56 g proteine karÅŸÄ±lÄ±k gelir (yaklaÅŸÄ±k 200 g piÅŸmiÅŸ tavuk gÃ¶ÄŸsÃ¼ veya 250 g yoÄŸurt + 2 yumurta + 60 g beyaz peynir) <sup>[2]</sup></li>
<li><strong>Sodyum kÄ±sÄ±tlamasÄ±:</strong> &lt;2 g/gÃ¼n (5 g tuz), kan basÄ±ncÄ± ve proteinÃ¼ri kontrolÃ¼nde etkinliÄŸi gÃ¶sterilmiÅŸtir <sup>[3]</sup></li>
<li><strong>Potasyum:</strong> Ã–zellikle RAS blokÃ¶rleri ve finerenon kullanan hastalarda dÃ¼zenli takip gerekir</li>
</ul>

<h3>Fiziksel Aktivite</h3>
<p>Haftada en az 150 dakika orta ÅŸiddetli aerobik aktivite ve haftada 2 gÃ¼n direnÃ§ antrenmanÄ± Ã¶nerilmektedir. GÃ¶zlemsel Ã§alÄ±ÅŸmalar dÃ¼zenli egzersizin eGFR dÃ¼ÅŸÃ¼ÅŸ hÄ±zÄ±nÄ± yavaÅŸlattÄ±ÄŸÄ±nÄ± gÃ¶stermektedir; ancak bu veriler henÃ¼z bÃ¼yÃ¼k randomize kontrollÃ¼ Ã§alÄ±ÅŸmalarla doÄŸrulanmamÄ±ÅŸtÄ±r <sup>[1]</sup>.</p>

<h3>Sigara BÄ±rakma</h3>
<p>Sigara kullanÄ±mÄ±, diyabetik nefropati progresyonu iÃ§in baÄŸÄ±msÄ±z bir risk faktÃ¶rÃ¼dÃ¼r. GÃ¶zlemsel kohort Ã§alÄ±ÅŸmalarÄ±, sigara iÃ§en diyabet hastalarÄ±nda albÃ¼minÃ¼ri geliÅŸme riskinin 1.6-2.0 kat arttÄ±ÄŸÄ±nÄ± gÃ¶stermektedir <sup>[1]</sup>.</p>

<h2>Farmakolojik Tedavi: GÃ¼ncel KanÄ±tlar</h2>

<h3>1. RAS BlokajÄ± â€” HÃ¢lÃ¢ Tedavinin Temeli</h3>

<p>ACE inhibitÃ¶rleri (ramipril, lisinopril) ve ARB'ler (losartan, valsartan, irbesartan) albÃ¼minÃ¼rik DKD'de birinci basamak tedavidir. Bu yaklaÅŸÄ±m 20 yÄ±lÄ± aÅŸkÄ±n sÃ¼redir gÃ¼Ã§lÃ¼ kanÄ±tlarla desteklenmektedir:</p>

<ul>
<li><strong>RENAAL Ã§alÄ±ÅŸmasÄ± (losartan):</strong> Son dÃ¶nem bÃ¶brek yetmezliÄŸi riskinde %28 azalma <sup>[4]</sup></li>
<li><strong>IDNT Ã§alÄ±ÅŸmasÄ± (irbesartan):</strong> Serum kreatinin dÃ¼zeyinin iki katÄ±na Ã§Ä±kma riskinde %33 azalma <sup>[5]</sup></li>
</ul>

<div class="warning-box">
<p><strong>âš ï¸ Ã–nemli:</strong> ACE inhibitÃ¶rÃ¼ ve ARB'nin birlikte kullanÄ±mÄ± (dual RAS blokajÄ±) Ã¶nerilmemektedir. ONTARGET Ã§alÄ±ÅŸmasÄ±, kombine kullanÄ±mda ek fayda olmaksÄ±zÄ±n akut bÃ¶brek hasarÄ± ve hiperkalemi riskinin arttÄ±ÄŸÄ±nÄ± gÃ¶stermiÅŸtir <sup>[6]</sup>.</p>
</div>

<h3>2. SGLT2 Ä°nhibitÃ¶rleri â€” GÃ¼Ã§lÃ¼ KanÄ±tlarla Desteklenen Yeni Standart</h3>

<p>SGLT2 inhibitÃ¶rleri (empagliflozin, dapagliflozin, canagliflozin) DKD tedavisinde son yÄ±llarÄ±n en Ã¶nemli geliÅŸmesidir. Birden fazla bÃ¼yÃ¼k randomize kontrollÃ¼ Ã§alÄ±ÅŸma tutarlÄ± bÃ¶brek koruyucu etki gÃ¶stermiÅŸtir:</p>

<table>
<thead>
<tr><th>Ã‡alÄ±ÅŸma</th><th>Ä°laÃ§</th><th>Primer SonlanÄ±m</th><th>Risk AzalmasÄ±</th><th>KanÄ±t DÃ¼zeyi</th></tr>
</thead>
<tbody>
<tr><td>CREDENCE <sup>[7]</sup></td><td>Canagliflozin</td><td>BÃ¶brek kompozit sonlanÄ±m</td><td>%30</td><td>RCT</td></tr>
<tr><td>DAPA-CKD <sup>[8]</sup></td><td>Dapagliflozin</td><td>eGFR dÃ¼ÅŸÃ¼ÅŸÃ¼, SDBY, renal/KV Ã¶lÃ¼m</td><td>%39</td><td>RCT</td></tr>
<tr><td>EMPA-KIDNEY <sup>[9]</sup></td><td>Empagliflozin</td><td>KBH progresyonu veya KV Ã¶lÃ¼m</td><td>%28</td><td>RCT</td></tr>
</tbody>
</table>

<div class="evidence-box">
<p><strong>ğŸŸ¢ KanÄ±t dÃ¼zeyi: YÃ¼ksek (Ã‡oklu RCT).</strong> KDIGO 2024, eGFR â‰¥20 mL/dk ve albÃ¼minÃ¼ri bulunan DKD hastalarÄ±nda SGLT2 inhibitÃ¶rlerini birinci sÄ±rada Ã¶nermektedir. Diyabet durumundan baÄŸÄ±msÄ±z olarak KBH'de fayda gÃ¶sterilmiÅŸtir (DAPA-CKD'de hastalarÄ±n %33'Ã¼ nondiyabetikti) <sup>[2]</sup>.</p>
</div>

<p><strong>Yan etki profili:</strong> Genital mantar enfeksiyonlarÄ± (%3-5), nadiren diyabetik ketoasidoz (&lt;%0.1), geÃ§ici eGFR dÃ¼ÅŸÃ¼ÅŸÃ¼ (baÅŸlangÄ±Ã§ta %5-10, hemodinamik, geri dÃ¶nÃ¼ÅŸÃ¼mlÃ¼). eGFR &lt;20'de baÅŸlangÄ±Ã§ Ã¶nerilmez, ancak kullanÄ±mda olan hastalarda diyalize kadar devam edilebilir.</p>

<h3>3. GLP-1 ReseptÃ¶r Agonistleri â€” BÃ¶brek Korumada YÃ¼kselen KanÄ±tlar</h3>

<p>GLP-1 reseptÃ¶r agonistlerinin (semaglutid, liraglutid, dulaglutid) kardiyovaskÃ¼ler yararlarÄ± iyi bilinmekle birlikte, bÃ¶brek koruyucu etkileri daha yakÄ±n zamanda kanÄ±tlanmÄ±ÅŸtÄ±r:</p>

<ul>
<li><strong>FLOW Ã§alÄ±ÅŸmasÄ± (semaglutid, 2024) <sup>[10]</sup>:</strong> DKD hastalarÄ±nda primer bÃ¶brek sonlanÄ±m noktasÄ±nda <strong>%24 risk azalmasÄ±</strong>. Ä°lk kez bir GLP-1 RA'nÄ±n primer bÃ¶brek sonlanÄ±m noktasÄ±na gÃ¶re tasarlanmÄ±ÅŸ bir Ã§alÄ±ÅŸmada olumlu sonuÃ§ verdiÄŸi Ã§alÄ±ÅŸma.</li>
<li><strong>LEADER (liraglutid):</strong> Sekonder bÃ¶brek sonlanÄ±mÄ±nda %22 risk azalmasÄ± <sup>[11]</sup></li>
<li><strong>AWARD-7 (dulaglutid):</strong> Orta-ileri KBH'de eGFR kaybÄ±nÄ± yavaÅŸlattÄ± <sup>[12]</sup></li>
</ul>

<div class="info-box">
<p><strong>ğŸ’¡ Klinik perspektif:</strong> FLOW Ã§alÄ±ÅŸmasÄ± GLP-1 RA'larÄ± DKD tedavisinde yeni bir konuma taÅŸÄ±mÄ±ÅŸtÄ±r. Ancak SGLT2 inhibitÃ¶rleri ile doÄŸrudan karÅŸÄ±laÅŸtÄ±rmalÄ± (head-to-head) bir Ã§alÄ±ÅŸma henÃ¼z yapÄ±lmamÄ±ÅŸtÄ±r. KDIGO 2024, GLP-1 RA'larÄ± tip 2 diyabetli KBH hastalarÄ±nda glisemik kontrol ve kardiyovaskÃ¼ler risk azaltma amacÄ±yla Ã¶nermektedir <sup>[2]</sup>.</p>
</div>

<h3>4. Nonsteroidal MRA'lar â€” Finerenon</h3>

<p>Finerenon, geleneksel MRA'lardan (spironolakton, eplerenon) farklÄ± olarak nonsteroidal yapÄ±da bir mineralokortikoid reseptÃ¶r antagonistidir:</p>

<ul>
<li><strong>FIDELIO-DKD <sup>[13]</sup>:</strong> Primer bÃ¶brek kompozit sonlanÄ±mda %18 risk azalmasÄ±</li>
<li><strong>FIGARO-DKD <sup>[14]</sup>:</strong> Primer kardiyovaskÃ¼ler kompozit sonlanÄ±mda %13 risk azalmasÄ±</li>
<li><strong>FIDELITY (havuzlanmÄ±ÅŸ analiz):</strong> Hem bÃ¶brek hem kardiyovaskÃ¼ler sonlanÄ±mlarda tutarlÄ± fayda</li>
</ul>

<div class="warning-box">
<p><strong>âš ï¸ Hiperkalemi riski:</strong> FIDELIO-DKD'de finerenon grubunda hiperkalemiye baÄŸlÄ± tedavi kesme oranÄ± %2.3 idi (plasebo %0.9). Serum potasyum dÃ¼zeyi baÅŸlangÄ±Ã§ta â‰¤4.8 mEq/L olmalÄ± ve tedavi sÄ±rasÄ±nda dÃ¼zenli izlenmelidir. RAS blokerleri ile birlikte kullanÄ±mda risk artar <sup>[13]</sup>.</p>
</div>

<h2>Tedavi AlgoritmasÄ±: Kime Ne Zaman?</h2>

<h3>Birincil Koruma (AlbÃ¼minÃ¼ri yok, eGFR normal)</h3>
<ol>
<li><strong>Glisemik kontrol:</strong> HbA1c hedefi bireyselleÅŸtirilmeli â€” genel olarak &lt;%7, hipoglisemi riski yÃ¼ksek hastalarda &lt;%8 (KDIGO 2024) <sup>[2]</sup></li>
<li><strong>Kan basÄ±ncÄ±:</strong> KDIGO 2021, albÃ¼minÃ¼rik KBH'de sistolik &lt;120 mmHg hedefini Ã¶nermektedir (tolere edildiÄŸinde) <sup>[15]</sup></li>
<li><strong>YÄ±llÄ±k tarama:</strong> UACR ve eGFR (tip 1 DM'de tanÄ±dan 5 yÄ±l sonra, tip 2 DM'de tanÄ± anÄ±ndan itibaren)</li>
<li><strong>YaÅŸam tarzÄ± mÃ¼dahaleleri:</strong> Beslenme, egzersiz, sigara bÄ±rakma</li>
</ol>

<h3>Ä°kincil Koruma (AlbÃ¼minÃ¼ri ve/veya eGFR dÃ¼ÅŸÃ¼klÃ¼ÄŸÃ¼ mevcut)</h3>
<ol>
<li><strong>RAS blokajÄ±:</strong> ACE inhibitÃ¶rÃ¼ veya ARB (albÃ¼minÃ¼ri varsa, maksimum tolere edilen doza titre et)</li>
<li><strong>SGLT2 inhibitÃ¶rÃ¼ ekle:</strong> eGFR â‰¥20 mL/dk ise (diyabet durumundan baÄŸÄ±msÄ±z)</li>
<li><strong>Finerenon ekle:</strong> SGLT2i + RAS blokajÄ±na raÄŸmen persistan albÃ¼minÃ¼ri (UACR â‰¥30 mg/g) ve potasyum â‰¤4.8 ise</li>
<li><strong>GLP-1 RA ekle:</strong> Ek glisemik kontrol veya kardiyovaskÃ¼ler risk azaltma gerekiyorsa</li>
<li><strong>Takip:</strong> eGFR ve UACR 3-6 ayda bir, potasyum dÃ¼zenli</li>
</ol>

<div class="evidence-box">
<p><strong>ğŸŸ¢ KDIGO 2024 4-sÃ¼tun yaklaÅŸÄ±mÄ±:</strong> RAS blokajÄ± + SGLT2i + ns-MRA + GLP-1 RA. Bu dÃ¶rt tedavi sÄ±nÄ±fÄ± farklÄ± patofizyolojik yolaklarÄ± hedefler ve kombine kullanÄ±mda aditif fayda beklenir. Ancak dÃ¶rt ilacÄ±n birlikte kullanÄ±ldÄ±ÄŸÄ± bÃ¼yÃ¼k Ã¶lÃ§ekli RCT verisi henÃ¼z mevcut deÄŸildir <sup>[2]</sup>.</p>
</div>

<h2>TÃ¼rkiye'de EriÅŸim</h2>

<p>Tedaviye eriÅŸim, klinik kararlarÄ± doÄŸrudan etkileyen bir faktÃ¶rdÃ¼r:</p>

<ul>
<li><strong>ACE inhibitÃ¶rleri / ARB'ler:</strong> SGK kapsamÄ±nda, geniÅŸ eriÅŸim</li>
<li><strong>SGLT2 inhibitÃ¶rleri:</strong> SGK kapsamÄ±nda, ancak geri Ã¶deme koÅŸullarÄ± diyabet tanÄ±sÄ± ve belirli HbA1c eÅŸiklerine baÄŸlÄ±dÄ±r. Nondiyabetik KBH endikasyonu henÃ¼z kapsam dÄ±ÅŸÄ±dÄ±r</li>
<li><strong>GLP-1 RA'lar:</strong> Semaglutid ve liraglutid SGK kapsamÄ±nda kÄ±sÄ±tlÄ± endikasyonlarla; doz ve sÃ¼re sÄ±nÄ±rlamalarÄ± mevcuttur</li>
<li><strong>Finerenon:</strong> TÃ¼rkiye'de ruhsat durumu ve SGK geri Ã¶deme kapsamÄ± gÃ¼ncellenmelidir â€” hastalarÄ±n eriÅŸimi sÄ±nÄ±rlÄ± olabilir</li>
</ul>

<h2>Gelecek Perspektifler</h2>

<p>DKD alanÄ±nda aktif olarak araÅŸtÄ±rÄ±lan yaklaÅŸÄ±mlar:</p>

<ul>
<li><strong>Dual GIP/GLP-1 agonistleri:</strong> Tirzepatid'in bÃ¶brek sonuÃ§larÄ± (devam eden Ã§alÄ±ÅŸmalar)</li>
<li><strong>Endotelin reseptÃ¶r antagonistleri:</strong> Atrasentan'Ä±n proteinÃ¼ri Ã¼zerindeki etkileri (SONAR Ã§alÄ±ÅŸmasÄ± sonrasÄ± geliÅŸmeler)</li>
<li><strong>Anti-fibrotik ajanlar:</strong> TGF-Î² yolaÄŸÄ±nÄ± hedefleyen molekÃ¼ller</li>
<li><strong>SGLT1/2 dual inhibitÃ¶rleri:</strong> Sotagliflozin</li>
</ul>

<h2>SonuÃ§</h2>

<p>DKD tedavisi son on yÄ±lda kÃ¶kten deÄŸiÅŸmiÅŸtir. RAS blokajÄ±nÄ±n yanÄ±na SGLT2 inhibitÃ¶rleri, GLP-1 RA'lar ve nonsteroidal MRA'lar eklenmiÅŸtir. Bu ajanlarÄ±n her biri farklÄ± mekanizmalarla bÃ¶brek ve kardiyovaskÃ¼ler koruma saÄŸlamaktadÄ±r.</p>

<p>Ancak birkaÃ§ noktayÄ± vurgulamak gerekir:</p>

<ul>
<li>Tedavi kararlarÄ± <strong>bireyselleÅŸtirilmelidir</strong> â€” eGFR, albÃ¼minÃ¼ri dÃ¼zeyi, kardiyovaskÃ¼ler risk, potasyum dÃ¼zeyi ve hastanÄ±n toleransÄ± gÃ¶z Ã¶nÃ¼nde bulundurulmalÄ±dÄ±r</li>
<li>Yeni ajanlarÄ±n uzun vadeli gÃ¼venlik profilleri hÃ¢lÃ¢ netleÅŸmektedir</li>
<li>DÃ¶rt tedavi sÄ±nÄ±fÄ±nÄ±n kombine kullanÄ±mÄ±na iliÅŸkin bÃ¼yÃ¼k Ã¶lÃ§ekli veri sÄ±nÄ±rlÄ±dÄ±r</li>
<li>TÃ¼rkiye'deki eriÅŸim ve geri Ã¶deme koÅŸullarÄ±, kÄ±lavuz Ã¶nerilerinin tam olarak uygulanmasÄ±nÄ± zorlaÅŸtÄ±rabilir</li>
</ul>

<p><strong>En Ã¶nemli mesaj:</strong> Diyabet hastalarÄ±nda dÃ¼zenli bÃ¶brek taramasÄ± ve erken mÃ¼dahale, bÃ¶brek fonksiyon kaybÄ±nÄ± Ã¶nemli Ã¶lÃ§Ã¼de yavaÅŸlatabilir. HastanÄ±z DKD riski taÅŸÄ±yorsa, gÃ¼ncel kÄ±lavuzlara uygun Ã§ok basamaklÄ± tedavi yaklaÅŸÄ±mÄ±nÄ± deÄŸerlendirin.</p>

</div>

<div class="warning-box">
<p>âš ï¸ <strong>Ã–nemli:</strong> Bu iÃ§erik saÄŸlÄ±k profesyonellerini ve halkÄ± bilgilendirme amaÃ§lÄ±dÄ±r; tÄ±bbi tavsiye yerine geÃ§mez. Bireysel tedavi kararlarÄ± iÃ§in mutlaka nefroloji veya endokrinoloji uzmanÄ±nÄ±za danÄ±ÅŸÄ±n.</p>
</div>

<div class="author-box">
<div class="author-avatar">UY</div>
<div class="author-info">
<h4>UzunYaÅŸa AraÅŸtÄ±rma Ekibi</h4>
<p>KanÄ±ta dayalÄ± saÄŸlÄ±k bilgisi â€” gÃ¼ncel kÄ±lavuzlar ve primer literatÃ¼rden derlenen iÃ§erikler.</p>
</div>
</div>

<h4>ğŸ“š Kaynaklar</h4>
<ol style="font-size: 0.9rem; color: #6b7280; line-height: 1.8;">
<li>Verma S, Katwal S, Akula HR, et al. Guideline-Directed Medical Therapy for Diabetic Kidney Disease. <em>Cureus.</em> 2026. <a href="https://doi.org/10.7759/cureus.101867" target="_blank" rel="noopener">doi:10.7759/cureus.101867</a></li>
<li>KDIGO 2024 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <em>Kidney Int.</em> 2024;106(5S):S1-S127.</li>
<li>McMahon EJ, et al. Altered dietary salt intake for people with chronic kidney disease. <em>Cochrane Database Syst Rev.</em> 2021;6:CD010070.</li>
<li>Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). <em>N Engl J Med.</em> 2001;345:861-869.</li>
<li>Lewis EJ, et al. Renoprotective effect of irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). <em>N Engl J Med.</em> 2001;345:851-860.</li>
<li>ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. <em>N Engl J Med.</em> 2008;358:1547-1559.</li>
<li>Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). <em>N Engl J Med.</em> 2019;380:2295-2306.</li>
<li>Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). <em>N Engl J Med.</em> 2020;383:1436-1446.</li>
<li>EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease (EMPA-KIDNEY). <em>N Engl J Med.</em> 2023;388:117-127.</li>
<li>Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). <em>N Engl J Med.</em> 2024;391:109-121.</li>
<li>Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes (LEADER renal). <em>N Engl J Med.</em> 2017;377:839-848.</li>
<li>Tuttle KR, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). <em>Diabetes Care.</em> 2018;41:2724-2731.</li>
<li>Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). <em>N Engl J Med.</em> 2020;383:2219-2229.</li>
<li>Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes (FIGARO-DKD). <em>N Engl J Med.</em> 2021;385:2252-2263.</li>
<li>KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. <em>Kidney Int.</em> 2021;99(3S):S1-S87.</li>
</ol>

<div class="cta-box">
<h3>ğŸ¯ SaÄŸlÄ±ÄŸÄ±nÄ±zÄ± DeÄŸerlendirin</h3>
<p>Ãœcretsiz araÃ§larÄ±mÄ±zla saÄŸlÄ±k durumunuzu deÄŸerlendirin.</p>
<a href="../araclar.html" class="cta-btn">AraÃ§larÄ± KeÅŸfet â†’</a>
</div>

<div style="text-align: center; margin: 2rem 0; padding: 1rem; background: #f8fafc; border-radius: 12px;">
<h4 style="margin-bottom: 0.5rem; color: var(--primary);">Bu yazÄ±yÄ± paylaÅŸÄ±n</h4>
<div style="display: flex; gap: 0.5rem; justify-content: center; flex-wrap: wrap;">
<a href="https://twitter.com/intent/tweet?text=Diyabetik%20B%C3%B6brek%20Hastal%C4%B1%C4%9F%C4%B1%3A%20G%C3%BCncel%20Tedavi%20Yakla%C5%9F%C4%B1mlar%C4%B1&url=https://uzunyasa.com/pages/blog/diyabetik-bobrek-hastaligi-yeni-tedavi-yontemleri-ve-koruma-.html" target="_blank" style="display: inline-block; padding: 0.5rem 1rem; background: #1DA1F2; color: white; text-decoration: none; border-radius: 6px; font-size: 0.85rem;">ğŸ¦ Twitter</a>
<a href="https://wa.me/?text=Diyabetik%20B%C3%B6brek%20Hastal%C4%B1%C4%9F%C4%B1%20tedavisinde%20g%C3%BCncel%20yakla%C5%9F%C4%B1mlar%20https://uzunyasa.com/pages/blog/diyabetik-bobrek-hastaligi-yeni-tedavi-yontemleri-ve-koruma-.html" target="_blank" style="display: inline-block; padding: 0.5rem 1rem; background: #25D366; color: white; text-decoration: none; border-radius: 6px; font-size: 0.85rem;">ğŸ“± WhatsApp</a>
<a href="https://www.linkedin.com/sharing/share-offsite/?url=https://uzunyasa.com/pages/blog/diyabetik-bobrek-hastaligi-yeni-tedavi-yontemleri-ve-koruma-.html" target="_blank" style="display: inline-block; padding: 0.5rem 1rem; background: #0077B5; color: white; text-decoration: none; border-radius: 6px; font-size: 0.85rem;">ğŸ’¼ LinkedIn</a>
</div>
</div>

    </article>

    <footer style="text-align: center; padding: 2rem; color: var(--text-gray); font-size: 0.85rem; border-top: 1px solid #e5e7eb; margin-top: 4rem;">
    <p>Â© 2026 UzunYaÅŸa. TÃ¼m haklarÄ± saklÄ±dÄ±r. â€¢ <a href="../../pages/privacy.html" style="color: var(--primary); text-decoration: none;">Gizlilik PolitikasÄ±</a></p>
    </footer>
</body>
</html>
